Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)
Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates if :
1 ) the plasma aldosterone concentration and blood pressure change in response to
roxithromycin could be useful for the screening of PA patients carrying a KCNJ5-mutated APA;
2) the change of PAC in response to mutated KCNJ5 channel is truly occurring in KCNJ5-mutated
APA.